Safety Study of 20,000 EU of Clinical Center Reference Endotoxin in Allergic Adults With and Without Mild Asthma
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Endotoxin is a component of outdoor air pollution, an air contaminant found in a number of different workplaces, and is even found in homes. The endotoxin used for this study is obtained from the National Institutes of Health, and is called "Clinical Center Reference Endotoxin", or CCRE. The purpose of this Phase 1 research study is to identify a dose of inhaled endotoxin that is safe (does not cause prolonged cough, shortness of breath or other problems), but causes changes in your sputum cell samples that the scientists can measure. Phase 1 research studies like this one are not intended to be a treatment, but are a scientific investigation. Eventually, with these types of studies we will be able to examine why some people are more sensitive to endotoxin. Scientists at other universities have found that while most people do not have a considerable lung response to endotoxin at doses as high as 60,000 EU (endotoxin units), a few respond to as little as a total dose of 4500 EU. Our study is designed to identify if using a dose of 20,000 EU causes changes in the lung cells but does not cause symptoms in our study subjects. In our previous studies in our lab, using an endotoxin from another source, we have used higher doses (15,000 EUs) in subjects with asthma with no major problems, and we have used 10,000 EUs of CCRE in subjects with allergies and asthma without problems. We have used 20,000 EUs of CCRE in healthy individuals with no major problems.
| Condition | Intervention | Phase |
|---|---|---|
|
Mild Allergic Rhinitis Mild Allergic Rhinitis With Mild Asthma |
Biological: Clinical Center Reference Endotoxin |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Safety Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Basic Science |
| Official Title: | Safety Study of 20,000 EU of Clinical Center Reference Endotoxin in Allergic Adults With and Without Mild Asthma |
- Increased sputum neutrophils with no adverse events [ Time Frame: 6 hours post challenge ] [ Designated as safety issue: Yes ]
| Enrollment: | 4 |
| Study Start Date: | May 2008 |
| Study Completion Date: | May 2012 |
| Primary Completion Date: | May 2012 (Final data collection date for primary outcome measure) |
-
Biological: Clinical Center Reference Endotoxin
Eligibility| Ages Eligible for Study: | 18 Years to 50 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Mild allergic rhinitis
- Mild allergic asthma
- Normal lung function
- No other chronic illness
Exclusion Criteria:
- Use of inhaled or oral steroids
- Emergency treatment of asthma in last year
- Inhaled tobacco use
Contacts and Locations| United States, North Carolina | |
| UNC Center for Environmental Medicine, Asthma and Lung Biology | |
| Chapel Hill, North Carolina, United States, 27599 | |
| Principal Investigator: | David b Peden, MD, MS | University of North Carolina |
More Information
No publications provided
| Responsible Party: | David B. Peden, MD, Professor of Pediatrics, University of North Carolina, Chapel Hill |
| ClinicalTrials.gov Identifier: | NCT00630461 History of Changes |
| Other Study ID Numbers: | 07-2026 GCRC 2627 |
| Study First Received: | February 28, 2008 |
| Last Updated: | October 5, 2012 |
| Health Authority: | United States: Federal Government United States: Food and Drug Administration United States: Institutional Review Board |
Keywords provided by University of North Carolina, Chapel Hill:
|
mild asthma, mild allergies |
Additional relevant MeSH terms:
|
Asthma Rhinitis Bronchial Diseases Respiratory Tract Diseases Lung Diseases, Obstructive Lung Diseases Respiratory Hypersensitivity |
Hypersensitivity, Immediate Hypersensitivity Immune System Diseases Nose Diseases Respiratory Tract Infections Otorhinolaryngologic Diseases |
ClinicalTrials.gov processed this record on May 19, 2013